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Abstract 
Purpose: Patients with Behçet’s disease often need intraocular surgeries for the 
treatment of secondary cataract or glaucoma. This study aims to report the clinical 
course before and after the intraocular surgeries of 5 patients who were systematically 
treated with infliximab.  
Methods: Retrospective case series.  
Results: Seven eyes of 5 male patients with Behçet’s disease, who underwent intraocular 
surgery while under systemic infliximab therapy at Yokohama City University Hospital 
from 2007 to 2009, were included in the study. The mean age at surgery was 44.2 years. 
Phacoemulsification was performed on 4 eyes, and trabeculectomy was done on the 
remaining 3 eyes. The mean duration since the onset of the ocular symptoms was 107 
months. Control of the ocular attacks with the use of other systemic medications was 
difficult for all patients; however, the use of infliximab enabled adequate control of the 
attacks. The visual acuity status during the preoperative stage did not worsen during the 
postoperative period. No infectious complication was observed in all cases.  Case Rep Ophthalmol 2011;2:189–192 
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Conclusions: Our results suggest that infliximab treatment does not complicate any 
subsequent intraocular surgery. Patients with Behçet’s disease in need of intraocular 
surgery can benefit from control of attacks with infliximab treatment. 
 
Introduction 
Behçet’s disease (BD) is characteristically an incurable systemic disease with recurrent 
inflammation [1–3]. In Japan, BD is known as one of the three major causes of uveitis. In 
general, uveitis is frequently associated with complicated cataract and secondary 
glaucoma [4, 5]. In some cases, surgical treatment is required. When surgical treatment of 
ocular inflammatory diseases is considered, control of the ocular inflammation before and 
after surgery is an important factor [4, 5]. For an ideal outcome of surgical treatment it is 
necessary that ocular inflammation has been under control for a few months prior to 
surgery [4]. Since the attacks of BD tend to be induced by surgical invasion [3], the 
decision to conduct surgery for BD is meticulous compared to other uveitis. However, 
there are cases of BD with uncontrollable uveitis, and such cases occasionally need 
surgical treatment. 
Infliximab is a monoclonal antibody against tumor necrosis factor-α (TNF-α) [3]. 
Infliximab has been approved for treatment of incurable BD uveoretinitis in Japan since 
2007, and definite promising effects have been noticed. On the other hand, the drug can 
possibly induce infectious complications of surgical treatment because of the systemic 
suppression of TNF-α [1, 2, 6–8]. 
This study presents 5 cases of BD with cataract and glaucoma surgeries under 
infliximab treatment. 
Case Reports 
Seven eyes of 5 patients with BD, who underwent intraocular surgery while under systemic 
infliximab therapy at Yokohama City University Hospital from 2007 to 2009, were included in the 
study. Patient characteristics are summarized in table 1. All patients were men, and the mean age at the 
time of surgery was 44.2 (30–70) years. Four eyes underwent phacoemulsification, while trabeculectomy 
was performed on the remaining 3 eyes. The mean duration since the onset of ocular symptoms was 110 
(34–180 months). Before infliximab was administered, all patients were systemically given colchicine, 
cyclosporine, and other immunosuppressive agents. However, control of the ocular attacks was difficult 
with the medicine administered, and the patients frequently experienced active ocular attacks. 
Fortunately, infliximab could suppress the severe ocular attacks in all patients. Infliximab therapy was 
administered at 5 mg/kg at 0, 2, and 6 weeks; after that, the infusion was administered every 8 weeks, 
except for patients b and e. Minor ocular attacks still occurred; thus, the infusion interval was decreased 
to every 6 weeks, which resulted in control of attacks. During the postoperative period, ocular attacks 
were observed in patients a and b; however, every attack was controlled with temporary medicines. All 
patients who underwent phacoemulsification recovered preoperative visual acuity status. Moreover, 
ocular tension was well controlled in all patients who had trabeculectomy. No infections were observed 
in any of the patients after surgery. Case Rep Ophthalmol 2011;2:189–192 
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Discussion 
Ever since infliximab has been available for the treatment of BD, its excellent efficacy 
against ocular attacks of BD has been reported [1–3, 6]. However, in cases where surgical 
treatment is considered, it is possible that infliximab might induce infections during the 
perioperative period because it suppresses cytokines for improved postoperative wound 
healing [1, 2, 7]. Surgical treatment of rheumatoid arthritis under infliximab therapy is 
recommended to be performed 4 weeks after infliximab infusion in order to assure a 
minimum systemic concentration of infliximab [1, 2, 7]. Previously, some patients with 
BD who underwent cataract surgery under systemic infliximab treatment were reported 
in Japan [1, 2]. The reports followed the rheumatic guidelines, and no remarkable 
complications were described in any cases. The patients recovered their preoperative 
visual acuity status.  
In the field of orthopedic surgery, it was previously reported that infliximab did not 
increase the risk of either infections or surgical complications occurring in patients with 
rheumatoid arthritis within 1 year of orthopedic surgery [7]. Furthermore, in the same 
field, previously reported complications were localized infections, and infliximab is 
considered to be relatively safer than the other anti-TNF-α drugs in the perioperative 
period. In our search of the literature, we could not find any report of a correlation 
between endophthalmitis or toxic anterior segment syndrome (TASS) and systemic 
immunosuppressive treatment. The localized infection-like wound complications could 
be a concern in the field of orthopedic surgery as well as ophthalmology. 
In our study, both glaucoma and cataract cases were encountered. Perioperative 
infection was more frequent among the glaucoma than cataract cases in the previous 
report [5]. However, there were no complications in all our glaucoma cases. Ocular 
inflammation after surgery could be controlled with medicine as well. Based on our 
limited sampling of infliximab-treated patients with BD, infliximab has the potential not 
to complicate any subsequent surgery, not only for cataract but also for glaucoma. To 
reach a clearer conclusion, a greater number of subjects is necessary as well as a 
comparison with cases without infliximab treatment. Although further investigation is 
needed, we suggest a possible efficacy of infliximab in intraocular surgeries of BD. 
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Table 1. Profile of patients 
Case  Age at  
surgery  
(years) 
Sex Type  Surgery  Duration   
since onset 
Attack after surgery  Medicine besides 
infliximab 
a 30  Male  Incomplete  R)  Lectomy  34  None  Topical 
        L) Phaco  41  Minor attack in the left 
eye after 8 months 
Topical 
Presurgery: RV = 20/600 (n.c.), LV = 20/1,000 (n.c.) → Postsurgery: RV = 20/600 (n.c.), LV = 20/200 (20/30) 
b  70  Male  Incomplete  R) Phaco  58  Major attack in the left  
eye and both eyes after  
9 and 16 months,  
respectively 
Topical and 
systemic short-
term 
administration  
and subtenon 
injection of steroid
Presurgery: RV = 20/600 (n.c.), LV = 20/200 → Postsurgery: RV = 20/200, LV = 20/200 
c 44  Male  Incomplete  R)  Lectomy  180  None  Topical 
Presurgery: RV = 20/600 (n.c.), LV = 20/200 → Postsurgery: RV = 20/200, LV = 20/200 
d 39  Male  Incomplete  R)  Phaco  155  None  Topical 
      L)  Phaco  157 None  Topical 
Presurgery: RV = HM (n.c.), LV = HM (n.c.) → Postsurgery: RV = 20/600 (n.c.), LV = (20/200) 
e 38  Male  Incomplete  R)  Lectomy  123  None  Topical 
Presurgery: RV = 20/1,000 (n.c.), LV = NLP → Postsurgery: RV = 20/1,000 (n.c.), LV = NLP 
Lectomy = trabeculectomy; Phaco = phacoemulsification; RV = right vision; LV = left vision; HM = hand motion; n.c. = non 
corrigible; NLP = no light perception. 
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